|
Therapy area
Autoimmune diseases e.g. rheumatoid arthritis, multiple sclerosis and neuropathic pain.
|
|
Phase
Preclinical optimization phase. |
Competitive edge
Cathepsin S inhibitors have the potential for
improved efficacy, fewer side-effects and better
cost-effectiveness than current autoimmune
therapies. |
Project data
- Highly potent compounds with exellent selectivity and pharmacokinetic properties identified
- Selected Cathepsin S inhibitor compounds are being evaluated in preclinical models of RA and neuropathic pain
|
|
|
